Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

PARP inhibitors in cancer therapy: promise, progress, and puzzles.

Ellisen LW.

Cancer Cell. 2011 Feb 15;19(2):165-7. doi: 10.1016/j.ccr.2011.01.047.

2.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111
3.

THE PAST IS IN THE PRESENT: READING THE WORK OF EDNA O'SHAUGHNESSY.

Zeavin L.

Psychoanal Q. 2016 Jan;85(1):211-20. doi: 10.1002/psaq.12066.

PMID:
26784723
4.
5.

PARP inhibitors in breast cancer: BRCA and beyond.

Rios J, Puhalla S.

Oncology (Williston Park). 2011 Oct;25(11):1014-25. Review.

6.

PARP inhibitors in breast cancer.

Telli ML, Ford JM.

Clin Adv Hematol Oncol. 2010 Sep;8(9):629-35. Review.

PMID:
21157412
7.

Therapeutic potential of PARP inhibitors for metastatic breast cancer.

Irshad S, Ashworth A, Tutt A.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1243-51. doi: 10.1586/era.11.52. Review.

PMID:
21916578
8.

Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.

Comen EA, Robson M.

Cancer J. 2010 Jan-Feb;16(1):48-52. doi: 10.1097/PPO.0b013e3181cf01eb. Review.

9.

PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, Rodríguez MI, Linares JL, de Almodóvar MR, Oliver FJ.

Free Radic Biol Med. 2009 Jul 1;47(1):13-26. doi: 10.1016/j.freeradbiomed.2009.04.008. Epub 2009 Apr 10. Review.

PMID:
19362586
10.

Chemopotentiation by PARP inhibitors in cancer therapy.

Tentori L, Graziani G.

Pharmacol Res. 2005 Jul;52(1):25-33. Review.

PMID:
15911331
11.

A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.

Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A.

DNA Repair (Amst). 2008 Dec 1;7(12):2010-9. doi: 10.1016/j.dnarep.2008.08.014. Epub 2008 Oct 15.

PMID:
18832051
12.

PARP inhibitors--current status and the walk towards early breast cancer.

Glendenning J, Tutt A.

Breast. 2011 Oct;20 Suppl 3:S12-9. doi: 10.1016/S0960-9776(11)70288-0. Review.

PMID:
22015278
13.

The potential of PARP inhibitors in genetic breast and ovarian cancers.

Drew Y, Calvert H.

Ann N Y Acad Sci. 2008 Sep;1138:136-45. doi: 10.1196/annals.1414.020.

PMID:
18837894
14.

PARP inhibitors in ovarian cancer.

Ledermann JA.

Ann Oncol. 2016 Apr;27 Suppl 1:i40-i44. doi: 10.1093/annonc/mdw094.

PMID:
27141070
15.

Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review.

Buege M, Mahajan PB.

Rev Recent Clin Trials. 2015;10(4):326-39. Review.

PMID:
26374559
16.

Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.

Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK.

J Nucl Med. 2013 Jun;54(6):913-21. doi: 10.2967/jnumed.112.111534. Epub 2013 Apr 5.

17.

Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.

Shibata H, Miuma S, Saldivar JC, Huebner K.

Cancer Sci. 2011 Oct;102(10):1882-8. doi: 10.1111/j.1349-7006.2011.02016.x. Epub 2011 Jul 21.

18.

PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.

Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, Denys H.

Acta Clin Belg. 2011 Jan-Feb;66(1):2-9. Review.

PMID:
21485757
19.

The role of PARP1 in the DNA damage response and its application in tumor therapy.

Wang Z, Wang F, Tang T, Guo C.

Front Med. 2012 Jun;6(2):156-64. doi: 10.1007/s11684-012-0197-3. Epub 2012 Jun 3. Review.

PMID:
22660976

Supplemental Content

Support Center